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Letter to Editor  
 
Crimean-congo hemorrhagic fever: treatment and  
control strategy in admitted patients 
 
Sir 
Crimean-Congo Hemorrhagic Fever (CCHF) is an acute, 
tick-borne viral, zoonotic disease with hemorrhagic 
manifestations and considerable mortality in humans. It was 
first observed in Crimea in 1944 and was first isolated in 
Africa (Congo) from a febrile patient in 1956. The virus is 
widely distributed around the world (1, 2). 
 CCHF is caused by an RNA virus. This virus has been 
classified as a Nairovirus genus from the family of 
Bunyaviridae (3). Clinical features usually include a rapid 
progression characterized by hemorrhage, myalgia and fever 
(2, 3). 
Sheep, goats and cattle develop high titers of virus in 
blood, but tend not to fall ill. Humans are usually infected 
with CCHF virus through a tick bite but in some special 
areas, which sheepherding is one of the most common jobs, 
the route of contamination could be different. People who 
work with livestock, animal herders and slaughterhouses 
workers are at risk of CCHF infection (3-5).  
CCHF cases occurring as an expected event in endemic 
areas should notify the clinicians in the international 
neighborhood. They should be aware of the probability of 
the importation of CCHF cases from endemic areas in the 
nosocomial setting, and of the potential transmission of the 
virus via tick-infested and infected imported livestock. Blood 
and secretion of the infected patients can spread the infection 
so, the medical laboratory staffs and health-care workers are 
another high-risk group. There are epidemiological 
differences in CCHF transmission in the different parts of 
the world (3-5). 
Studies about pathogenesis of CCHF reveal endothelial 
damage resulting from either direct infection of the cells and 
indirect effect of viral and host factors
 [3,4]
. The nature of 
viral disease like CCHF is nonstop, progressive and/or self-
limited; so intensive care and patient physiology play an 
important role in the outcome of the patient. CCHF is an 
acute infection without any long-term sequelae or disability, 
the only relevant outcome is survival. 
Treatment for CCHF is primarily supportive and 
pharmaceutical options for CCHF treatment are limited (2, 3,  
 
7). CCHF patients need careful attention to the fluid and 
electrolyte balance, ventilation support for enough 
oxygenation, mild sedation and hemodynamic support 
depending upon the situation at the early stages of the 
disease in early stage of the disease presentation. Delay in 
the diagnosis and supportive care decreases the efficacy of 
treatment and aggravates the outcome of the disease. 
Some of the patients needed preparations of erythrocytes, 
platelets, and fresh frozen plasma, depending on their 
homeostatic state. Replacement therapy with blood products, 
according to the results of the complete blood count, is 
indispensable in the management of severe CCHF cases. 
Ribavirin (a synthetic purine nucleoside analogue) has 
been shown to inhibit viral replication of the CCHF virus in 
vitro (7). The World Health Organization (WHO) currently 
recommends the administration of ribavirin, oral or 
intravenous as a potential therapeutic drug for CCHF, but its 
efficacy in the treatment is controversial and some studies 
have shown that oral ribavirin treatment in CCHF patients do 
not affect on viral load or disease progression (2, 6, 7). 
Based on our observation, ribavirin prescription in early 
diagnosed patients had been associated with higher survival 
rates, shorter recovery time, and earlier return to normal 
levels of laboratory parameters (2). Treatment with ribavirin 
in suspected cases and post exposure prophylaxis for 
healthcare workers potentially exposed to CCHF virus 
should be considered (8). 
According to the clinical responses that were seen in 
most of the patients who were prescribed with ribavirin 
accompanied with corticosteroids for treatment or 
prophylaxis, it could be concluded that this strategy could be 
considered as a standard treatment or prophylactic protocol 
(2, 5-7).  
We believe a real uncertainty exists over the benefit of 
intensive care unit preparation for the treatment of CCHF, 
accompanied with intravenous ribavirin and corticosteroids 
prescription (3, 7). Intensive care for the admitted patients on 
one hand, improves the patient’s outcome and on the other 
hand it has a major role in disease control because treatment 
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protocols and protection strategies in intensive care unit is 
more sophisticated. 
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